Hikma Pharmaceuticals plc (HIK.L, HKMPY, HKMPF) announced Monday the launch of COMBOGESIC IV (acetaminophen and ibuprofen) injection in the US.COMBOGESIC IV is an intravenous, opioid-free pain relief medicine that is a combination of 1,000 mg of acetaminophen and 300 mg of ibuprofen, a nonsteroidal anti-inflammatory drug or NSAID.The drug was approved by the US FDA in October 2023 for use in adults where an intravenous route of administration is considered clinically necessary for the relief of mild to moderate pain, as well as the management of moderate to severe pain as an adjunct to opioid analgesics.In a Phase 3 clinical trial, COMBOGESIC IV provided more than double the pain relief than that of acetaminophen IV and ibuprofen IV alone, the company noted.Hikma in 2021 signed an exclusive license and distribution agreement with AFT Pharmaceuticals for the commercialization of COMBOGESIC IV in the US..
Hikma Pharmaceuticals plc（HIK.L，HKMPY，HKMPF）周一宣布在美国推出COMBOGESIC IV（对乙酰氨基酚和布洛芬）注射液。COMBOGESIC IV是一种静脉注射的无阿片类镇痛药，由1000毫克对乙酰氨基酚和300毫克布洛芬（一种非甾体抗炎药或NSAID）组成。该药物于2023年10月被美国FDA批准用于成人，在成人中，静脉给药途径被认为是缓解轻度至中度疼痛以及作为阿片类镇痛药辅助治疗中度至重度疼痛的临床必要途径。该公司指出，在一项3期临床试验中，COMBOGESIC IV的止痛效果是单独使用对乙酰氨基酚IV和布洛芬IV的两倍以上。Hikma于2021年与AFT Pharmaceuticals签署了一份独家许可和分销协议，用于COMBOGESIC IV在美国的商业化。。
